JP7737721B2 - 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 - Google Patents

認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Info

Publication number
JP7737721B2
JP7737721B2 JP2022537497A JP2022537497A JP7737721B2 JP 7737721 B2 JP7737721 B2 JP 7737721B2 JP 2022537497 A JP2022537497 A JP 2022537497A JP 2022537497 A JP2022537497 A JP 2022537497A JP 7737721 B2 JP7737721 B2 JP 7737721B2
Authority
JP
Japan
Prior art keywords
compound
cognitive impairment
disorder
isomer
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022537497A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507569A5 (https=
JP2023507569A (ja
Inventor
ブリュー メコネン，
ジョン エー． ブテラ，
ジャンシン フアン，
ヘマントバイ パテル，
チン ジャン，
ロバート ジェイソン ハー，
エミリー エリザベス フリーマン，
ニコラス ジェイムズ メーヒュー，
Original Assignee
エージンバイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エージンバイオ， インコーポレイテッド filed Critical エージンバイオ， インコーポレイテッド
Publication of JP2023507569A publication Critical patent/JP2023507569A/ja
Publication of JP2023507569A5 publication Critical patent/JP2023507569A5/ja
Priority to JP2025075567A priority Critical patent/JP2025107315A/ja
Application granted granted Critical
Publication of JP7737721B2 publication Critical patent/JP7737721B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022537497A 2019-12-19 2020-12-18 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 Active JP7737721B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025075567A JP2025107315A (ja) 2019-12-19 2025-04-30 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962950886P 2019-12-19 2019-12-19
US62/950,886 2019-12-19
PCT/US2020/066182 WO2021127543A1 (en) 2019-12-19 2020-12-18 Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025075567A Division JP2025107315A (ja) 2019-12-19 2025-04-30 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Publications (3)

Publication Number Publication Date
JP2023507569A JP2023507569A (ja) 2023-02-24
JP2023507569A5 JP2023507569A5 (https=) 2023-12-21
JP7737721B2 true JP7737721B2 (ja) 2025-09-11

Family

ID=76478828

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022537497A Active JP7737721B2 (ja) 2019-12-19 2020-12-18 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
JP2025075567A Pending JP2025107315A (ja) 2019-12-19 2025-04-30 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025075567A Pending JP2025107315A (ja) 2019-12-19 2025-04-30 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Country Status (8)

Country Link
US (1) US20230098667A1 (https=)
EP (1) EP4077333A4 (https=)
JP (2) JP7737721B2 (https=)
CN (1) CN115175911A (https=)
AU (1) AU2020405233A1 (https=)
IL (1) IL294031A (https=)
MX (1) MX2022007725A (https=)
WO (1) WO2021127543A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180170941A1 (en) * 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2020234880A1 (en) * 2019-05-23 2020-11-26 Life Guard Electrooptic Ltd. System and a method for surveilling swimmers
US20260033761A1 (en) 2022-07-29 2026-02-05 Hoffmann-La Roche Inc. Characterisation of neurological dysfunction
CN120584115A (zh) * 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500334A (ja) 2013-12-20 2017-01-05 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392119B (es) * 2015-06-19 2025-03-11 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo
CN116075302A (zh) * 2020-07-10 2023-05-05 艾吉因生物股份有限公司 GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法
WO2022011314A1 (en) * 2020-07-10 2022-01-13 Agenebio, Inc. POLYMORPHS OF A GABAA α5 AGONIST AND METHODS OF USING IN THE TREATMENT OF COGNITIVE IMPAIRMENT

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017500334A (ja) 2013-12-20 2017-01-05 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7514534B2 (ja) 2018-06-19 2024-07-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorg. Med. Chem. Lett.，2009年，Vol.19，pp.5746-5752

Also Published As

Publication number Publication date
JP2025107315A (ja) 2025-07-17
IL294031A (en) 2022-08-01
MX2022007725A (es) 2022-07-19
CN115175911A (zh) 2022-10-11
EP4077333A1 (en) 2022-10-26
US20230098667A1 (en) 2023-03-30
EP4077333A4 (en) 2024-01-10
WO2021127543A1 (en) 2021-06-24
JP2023507569A (ja) 2023-02-24
AU2020405233A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
US11142529B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12528819B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12291535B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12024525B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7737721B2 (ja) 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法
US11505555B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20240132513A1 (en) Benzazepine derivatives, compositions, and methods for treating cognitive impairment
HK40077472A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK40081455A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1230170B (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250430

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250725

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250825

R150 Certificate of patent or registration of utility model

Ref document number: 7737721

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150